Resistant Hypertension- A Review of Management Strategies

Dharmendra Jain, Niraj Kumar


Resistant hypertension (RH) is defined as the condition in which the blood pressure remains above goal in spite of concurrent use of 3 antihypertensive agents of different classes. Prevalence of resistant hypertension is 10-20% of the general hypertensive population. Patients with resistant hypertension are at high risk for adverse cardiovascular events. After excluding pseudoresistance, two most important causes of resistant hypertension are concomitant use of drugs and secondary causes. Management includes careful selection of antihypertensive drugs, lifestyle changes, treatment of secondary causes of hypertension, and discontinuation/ minimizing drugs that can cause hypertension. Invasive treatment option at present is an era to be explored.


Hypertension, pseudoresistant hypertension, truly resistant hypertension, white- coat effect

Full Text:




Calhoun DA, Jones D, Textor H et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Hypertension 2008; 51: 1403-1419.

Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis, Circulation 2012; 125: 1594-6.

Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients, Circulation 2012; 125: 635-42.

Lloyd-Jones DM, Evans JC, Larson MG et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community, Hypertension 2000; 36: 594-9.

Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT), J Clin Hypertens (Greenwich) 2002; 4: 393-404.

Williams B. The aorta and resistant hypertension, J Am Coll Cardiol 2009; 53: 452-4.

Brown MJ. Personalised medicine for hypertension, BMJ 2011; 343: d 4697.

Williams B. Resistant hypertension: an unmet treatment need, Lancet 2009; 374: 1396-8.

Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9: 399–405.

Bhatt DL, Kandzari DE, O’Neill WW et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.


  • There are currently no refbacks.

Comments on this article

View all comments